NASDAQ:FDMT 4D Molecular Therapeutics Q3 2023 Earnings Report $7.40 +0.80 (+12.12%) Closing price 04:00 PM EasternExtended Trading$7.35 -0.05 (-0.68%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast 4D Molecular Therapeutics EPS ResultsActual EPS-$0.24Consensus EPS -$0.67Beat/MissBeat by +$0.43One Year Ago EPSN/A4D Molecular Therapeutics Revenue ResultsActual Revenue$20.20 millionExpected Revenue$6.41 millionBeat/MissBeat by +$13.79 millionYoY Revenue GrowthN/A4D Molecular Therapeutics Announcement DetailsQuarterQ3 2023Date11/9/2023TimeN/AConference Call DateThursday, November 9, 2023Conference Call Time4:00PM ETUpcoming Earnings4D Molecular Therapeutics' Q3 2025 earnings is scheduled for Wednesday, November 12, 2025, with a conference call scheduled on Friday, November 7, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) 4D Molecular Therapeutics Earnings Headlines4DMT Announces New Employment Inducement GrantsSeptember 12, 2025 | globenewswire.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $30.40 Consensus Target Price from AnalystsSeptember 11, 2025 | americanbankingnews.comWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026. If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest.September 22 at 2:00 AM | SmartAsset (Ad)4D Molecular Therapeutics, Inc. (FDMT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 9, 2025 | seekingalpha.comJim Cramer on 4D Molecular Therapeutics: “This is a Pure Spec”September 5, 2025 | insidermonkey.com4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA ReadinessSeptember 2, 2025 | globenewswire.comSee More 4D Molecular Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like 4D Molecular Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 4D Molecular Therapeutics and other key companies, straight to your email. Email Address About 4D Molecular Therapeutics4D Molecular Therapeutics (NASDAQ:FDMT), founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches. 4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas. Notable programs target inherited retinal disorders—such as X-linked retinitis pigmentosa and achromatopsia—as well as investigational candidates for neuromuscular and metabolic diseases. By tailoring capsid design to specific tissues, the company seeks to optimize safety and efficacy in patient populations with high unmet medical need. To support its research and development efforts, 4D Molecular Therapeutics engages in collaborations with academic institutions and industry partners in the United States and Europe. The company completed its initial public offering in October 2017, trading on the NASDAQ under the symbol FDMT, and has used the proceeds to advance its clinical and preclinical programs. The company is led by President and Chief Executive Officer John J. Falcon, whose leadership team comprises experienced professionals in gene therapy development, regulatory affairs and commercial strategy. Under Falcon’s guidance, 4D Molecular Therapeutics continues to advance its innovative platform with the goal of delivering transformative treatments to patients suffering from rare genetic disorders.View 4D Molecular Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Berkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into Believers Upcoming Earnings Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025)Citigroup (10/14/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
